Jacobus R. B. J. Brouwers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacobus R. B. J. Brouwers has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anton J. M. Loonen
University of Groningen
2 shared publications - Arkady Valentinovich Semke
Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia
2 shared publications - Bob Wilffert
Groningen Research Institute of Pharmacy, Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands
2 shared publications - Olga Yu. Fedorenko
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 643000, Russia
2 shared publications - Svetlana Anatolievna Ivanova
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences
2 shared publications - Abraham Bèr Beckers
Department of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, the Netherlands; NUTRIM school of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 29 January 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (8) , 2273-2285
Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-blind, Placebo-controlled Trial
- 29 January 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (8) , 2273-2285
Top Cited PapersOpen AccessTailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-blind, Placebo-controlled Trial
- Open Access
- 12 July 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (9) , 1365-1371
Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation
Purpose: Atrial fibrillation (AF) is common in the elderly population and is associated with a high risk of thromboembolic events. Although non-vitamin K oral anticoagulants (NOACs) are the preferred drugs in antithrombotic therapy for AF, Vitamin K Anticoagulant drug (VKA) treatment is still used in a considerable proportion of patients with AF. Moreover, recent findings revealed that switching VKA to NOAC is associated with more bleeding complications in frail older patients with AF. Standard of care (SOC) monitoring of VKA treatment consists of venous blood sampling and back office dosage advice with a chain of processes and involvement of several health care professionals. We have designed a new procedure for monitoring (Near Patient Therapeutic Monitoring / NPTM) in order to improve the quality and safety of VKA treatment. NPTM consists of INR measurement with a point-of-care (POC) device in the home setting of a patient, performed by one professional and with an instant dosage advice. Methods: This is a cluster-randomised, parallel group, open label study to compare SOC with NPTM of VKA treatment in patients in a home setting. The follow-up period was one year. The primary outcome was time in therapeutic range (TTR), and secondary outcomes were adverse events (deaths, bleeding and thromboembolic events). Results: 555 Patients were included in the study. After randomisation, 271 patients received SOC and 284 patients received NPTM. The TTR did not differ significantly: 63.71% versus 62.47% (p > 0.05) for SOC and NPTM, respectively. Significant differences were found for all-cause death (SOC n = 34 versus NPTM n = 16, p < 0.05, OR 0.47, 95% CI: 0.25–0.87), total number of minor bleedings (79 events in SOC vs 52 in NPTM, p < 0.05, OR 64 (95%CI: 0,37–0,81) and all non-major bleedings (100 events in SOC vs 67 in NPTM, p < 0.05, OR 0.62 (95% CI: 043–0.90). Conclusions: NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC.
- 12 July 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (9) , 1365-1371
Open AccessOptimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation
Purpose: Atrial fibrillation (AF) is common in the elderly population and is associated with a high risk of thromboembolic events. Although non-vitamin K oral anticoagulants (NOACs) are the preferred drugs in antithrombotic therapy for AF, Vitamin K Anticoagulant drug (VKA) treatment is still used in a considerable proportion of patients with AF. Moreover, recent findings revealed that switching VKA to NOAC is associated with more bleeding complications in frail older patients with AF. Standard of care (SOC) monitoring of VKA treatment consists of venous blood sampling and back office dosage advice with a chain of processes and involvement of several health care professionals. We have designed a new procedure for monitoring (Near Patient Therapeutic Monitoring / NPTM) in order to improve the quality and safety of VKA treatment. NPTM consists of INR measurement with a point-of-care (POC) device in the home setting of a patient, performed by one professional and with an instant dosage advice. Methods: This is a cluster-randomised, parallel group, open label study to compare SOC with NPTM of VKA treatment in patients in a home setting. The follow-up period was one year. The primary outcome was time in therapeutic range (TTR), and secondary outcomes were adverse events (deaths, bleeding and thromboembolic events). Results: 555 Patients were included in the study. After randomisation, 271 patients received SOC and 284 patients received NPTM. The TTR did not differ significantly: 63.71% versus 62.47% (p > 0.05) for SOC and NPTM, respectively. Significant differences were found for all-cause death (SOC n = 34 versus NPTM n = 16, p < 0.05, OR 0.47, 95% CI: 0.25–0.87), total number of minor bleedings (79 events in SOC vs 52 in NPTM, p < 0.05, OR 64 (95%CI: 0,37–0,81) and all non-major bleedings (100 events in SOC vs 67 in NPTM, p < 0.05, OR 0.62 (95% CI: 043–0.90). Conclusions: NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC.
- 4 September 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (11) , 2479-2486
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary
Biosimilars of low molecular weight heparins (LMWHs) are more alike the originator than different branded LMWHs. The latter differ largely in molecular weight, anti-FXa/anti-FIIa ratio and antithrombin binding. The Food and Drug Administration and European Medicines Agency guidelines are sufficient for the clinical use of high quality LMWHs. However, the Food and Drug Administration guideline lacks the results of a phase I clinical trial in the approval process. Most information about biosimilars is available for enoxaparin given that many biosimilars of enoxaparin have received market access. The guidelines of many International Thrombosis Societies for LMWH biosimilars are too stringent, not updated and impractical for formulary uptake discussions. This review gives background information on critical factors for the formulary uptake process of LMWHs with special attention for the use of the System of Objectified Judgment Analysis/Infomatrix model.
- 4 September 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (11) , 2479-2486
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary
Biosimilars of low molecular weight heparins (LMWHs) are more alike the originator than different branded LMWHs. The latter differ largely in molecular weight, anti-FXa/anti-FIIa ratio and antithrombin binding. The Food and Drug Administration and European Medicines Agency guidelines are sufficient for the clinical use of high quality LMWHs. However, the Food and Drug Administration guideline lacks the results of a phase I clinical trial in the approval process. Most information about biosimilars is available for enoxaparin given that many biosimilars of enoxaparin have received market access. The guidelines of many International Thrombosis Societies for LMWH biosimilars are too stringent, not updated and impractical for formulary uptake discussions. This review gives background information on critical factors for the formulary uptake process of LMWHs with special attention for the use of the System of Objectified Judgment Analysis/Infomatrix model.
- Open Access
- 1 April 2014
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 50, 172-177
Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
- 1 April 2014
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 50, 172-177
Open AccessDehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
- 15 May 2012
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 27 (3) , 334-337
No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia
Background: The adenosine A2A receptor forms a heteromeric complex with the striatal dopamine D2 receptor. We examined whether a specific polymorphism in adenosine A2A receptor (2592 C/Tins) is associated with tardive dyskinesia.Methods: Tardive dyskinesia was assessed cross‐sectionally in 146 Caucasian psychiatric inpatients from Siberia.Results: Between‐group comparisons of genotypic or allelic frequencies showed no statistically significant difference. Logistic regression analysis with the occurrence of tardive dyskinesia as dependent variable showed no significant association with age, duration of illness, gender, and genotype.Conclusion: The interaction between the A2A and D2 receptors seems not involved in the development of tardive dyskinesia. Copyright © 2012 John Wiley & Sons, Ltd.
- 15 May 2012
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 27 (3) , 334-337
No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia
Background: The adenosine A2A receptor forms a heteromeric complex with the striatal dopamine D2 receptor. We examined whether a specific polymorphism in adenosine A2A receptor (2592 C/Tins) is associated with tardive dyskinesia.Methods: Tardive dyskinesia was assessed cross‐sectionally in 146 Caucasian psychiatric inpatients from Siberia.Results: Between‐group comparisons of genotypic or allelic frequencies showed no statistically significant difference. Logistic regression analysis with the occurrence of tardive dyskinesia as dependent variable showed no significant association with age, duration of illness, gender, and genotype.Conclusion: The interaction between the A2A and D2 receptors seems not involved in the development of tardive dyskinesia. Copyright © 2012 John Wiley & Sons, Ltd.
- 1 April 2004
- Published by Springer Nature in Pharmacy World & Science
- Vol. 26 (2) , 66-78
Oral antiarrhythmic drugs in converting recent onset atrial fibrillation
Aim: This article reviews clinical studies on oral antiarrhythmic drugs in converting recent onset atrial fibrillation. An oral loading dose of an antiarrhythmic drug for cardioversion of atrial...
- 1 April 2004
- Published by Springer Nature in Pharmacy World & Science
- Vol. 26 (2) , 66-78
Oral antiarrhythmic drugs in converting recent onset atrial fibrillation
Aim: This article reviews clinical studies on oral antiarrhythmic drugs in converting recent onset atrial fibrillation. An oral loading dose of an antiarrhythmic drug for cardioversion of atrial...